Thus, further tests of the anticancer active indole-based compounds using various liver tumor cell lines with aberrant p53 appear to be very promising in the light of the described results from the couple of HCT-116 p53-wildtype and knockout colon cancer cell lines. This evidence concerns the gene TP53 and colonic neoplasm.